ArticleFrontiers in immunology2020

Targeting Indoleamine 2,3-Dioxygenase in Cancer Models Using the Novel Small Molecule Inhibitor NTRC 3883-0.

Yvonne Grobben et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.